Jade Biosciences Plans Public Offering of Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Jade Biosciences announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, in a proposed underwritten public offering. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering are being offered by Jade. Jade intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents, and investments, to fund clinical trials, preclinical studies, and manufacturing in support of its programs, as well as for additional research and development activities, capital expenditures, working capital and other general corporate purposes. Jefferies, TD Cowen and UBS Investment Bank are acting as joint book-running managers for the proposed offering. LifeSci Capital is also acting as a book-running manager for the proposed offering. BTIG is acting as a lead manager for the proposed offering.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JBIO
Wall Street analysts forecast JBIO stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.300
Low
17.00
Averages
23.75
High
28.00
Current: 21.300
Low
17.00
Averages
23.75
High
28.00
About JBIO
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jade Biosciences Appoints New Board Member
- New Board Member: Jade Biosciences appointed Dr. Mark Eisner to its Board of Directors effective June 25, 2026, bringing over 25 years of biopharmaceutical experience that will be crucial as the company rapidly advances its antibody therapies.
- Extensive Industry Background: Dr. Eisner previously served as Chief Medical Officer at Vir Biotechnology, overseeing clinical development and regulatory affairs, and held key positions at Sonoma Biotherapeutics and FibroGen, showcasing his deep expertise in immunology.
- Strategic Development Focus: His addition is expected to enhance Jade's efforts in developing best-in-class therapies for autoimmune diseases, particularly the clinical advancement of its lead candidate, JADE101, addressing significant unmet patient needs.
- Future Outlook: Jade Biosciences is dedicated to innovating therapies for autoimmune diseases, and Dr. Eisner's experience will provide strategic guidance in regulatory approvals and commercialization processes, driving the success of its product pipeline.
See More
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
Jade Biosciences Prices Public Offering at $150 Million
- Offering Size: Jade Biosciences has priced its public offering at $15.00 per share for 10 million shares, expecting gross proceeds of $150 million, which will be allocated to clinical trials and R&D activities, enhancing the company's competitive edge in the biotech sector.
- Clinical Trial Progress: The lead investigational candidate, JADE101, is currently undergoing a Phase 2 clinical trial for treating immunoglobulin A nephropathy, and successful advancement could significantly elevate the company's market position in this therapeutic area.
- Underwriter Arrangement: Jade has granted underwriters a 30-day option to purchase an additional 1.5 million shares at the public offering price, providing flexibility that could secure additional funding to further support its R&D initiatives.
- Market Performance: JBIO shares have traded between $6.57 and $28.00 over the past year, closing at $17.59, and despite a recent drop of 7.02% to $16.35, the successful offering will ensure financial backing for the company's future growth.
See More
Jade Biosciences Prices Public Offering at $15 per Share
- Offering Size: Jade Biosciences has announced a public offering of 10 million shares priced at $15.00 each, expected to raise gross proceeds of $150 million, which will significantly support the company's clinical trials and R&D efforts.
- Use of Proceeds: The funds raised will be allocated to clinical trials, preclinical studies, and manufacturing, as well as capital expenditures, working capital, and other general corporate purposes, ensuring the company's sustained growth in the future.
- Underwriter Lineup: Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the offering, with LifeSci Capital and BTIG also involved, reflecting strong market confidence in the company.
- Additional Share Option: Underwriters have a 30-day option to purchase up to 1.5 million additional shares at the same price, providing further funding flexibility and enhancing investor confidence in the offering.
See More
Jade Biosciences Prices Public Offering at $150 Million
- Public Offering Pricing: Jade Biosciences has announced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 million before underwriting discounts, which will significantly bolster its financial resources to support clinical trials and R&D activities.
- Underwriter Arrangement: The offering is managed by Jefferies, TD Cowen, and UBS Investment Bank as joint book-running managers, with LifeSci Capital as a passive book-running manager and BTIG as a lead manager, reflecting strong market confidence in the company.
- Use of Proceeds: Jade intends to utilize the net proceeds from this offering for clinical trials, preclinical studies, manufacturing, and additional R&D activities, aiming to accelerate the development of its therapies for autoimmune diseases and further solidify its market position.
- Compliance and Transparency: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 15, 2026, ensuring compliance and transparency, which enhances investor confidence in the company's future growth prospects.
See More
Jade Biosciences Appoints New Board Member
- New Board Member: Jade Biosciences appointed Dr. Mark Eisner to its Board of Directors effective June 25, 2026, bringing over 25 years of biopharmaceutical experience that will be crucial as the company rapidly advances its antibody therapies.
- Extensive Industry Background: Dr. Eisner previously served as Chief Medical Officer at Vir Biotechnology, overseeing clinical development and regulatory affairs, and held key positions at Sonoma Biotherapeutics and FibroGen, showcasing his deep expertise in immunology.
- Strategic Development Focus: His addition is expected to enhance Jade's efforts in developing best-in-class therapies for autoimmune diseases, particularly the clinical advancement of its lead candidate, JADE101, addressing significant unmet patient needs.
- Future Outlook: Jade Biosciences is dedicated to innovating therapies for autoimmune diseases, and Dr. Eisner's experience will provide strategic guidance in regulatory approvals and commercialization processes, driving the success of its product pipeline.
See More
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Latest Wall Street Ratings Overview
- Morgan Stanley Bullish on Onto Innovation: Morgan Stanley initiates Onto Innovation with an overweight rating, citing potential upside to consensus estimates driven by its process control capabilities in both front-end and back-end operations, suggesting a favorable re-rating ahead.
- Needham Initiates Ceva as Buy: Needham launches coverage of Ceva with a Buy rating and a price target of $55, indicating a 70x P/E based on CY27 EPS estimates, as the company is positioned to benefit from AI advancements in the semiconductor sector.
- UBS Initiates Jade Biosciences as Buy: UBS rates Jade Biosciences as a Buy, highlighting its best-in-class potential, with expectations that the FDA's acceptance of shorter eGFR kidney function data will expedite enrollment in pivotal studies.
- Morgan Stanley Upgrades Ferrari: Morgan Stanley upgrades Ferrari to overweight from equal weight, raising the price target to $438, arguing that the current de-rating overstates brand risk and that the company’s wealth creation and product pipeline support a positive re-rating.
See More
Jade Biosciences Prices Public Offering at $150 Million
- Offering Size: Jade Biosciences has priced its public offering at $15.00 per share for 10 million shares, expecting gross proceeds of $150 million, which will be allocated to clinical trials and R&D activities, enhancing the company's competitive edge in the biotech sector.
- Clinical Trial Progress: The lead investigational candidate, JADE101, is currently undergoing a Phase 2 clinical trial for treating immunoglobulin A nephropathy, and successful advancement could significantly elevate the company's market position in this therapeutic area.
- Underwriter Arrangement: Jade has granted underwriters a 30-day option to purchase an additional 1.5 million shares at the public offering price, providing flexibility that could secure additional funding to further support its R&D initiatives.
- Market Performance: JBIO shares have traded between $6.57 and $28.00 over the past year, closing at $17.59, and despite a recent drop of 7.02% to $16.35, the successful offering will ensure financial backing for the company's future growth.
See More
Jade Biosciences Prices Public Offering at $15 per Share
- Offering Size: Jade Biosciences has announced a public offering of 10 million shares priced at $15.00 each, expected to raise gross proceeds of $150 million, which will significantly support the company's clinical trials and R&D efforts.
- Use of Proceeds: The funds raised will be allocated to clinical trials, preclinical studies, and manufacturing, as well as capital expenditures, working capital, and other general corporate purposes, ensuring the company's sustained growth in the future.
- Underwriter Lineup: Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the offering, with LifeSci Capital and BTIG also involved, reflecting strong market confidence in the company.
- Additional Share Option: Underwriters have a 30-day option to purchase up to 1.5 million additional shares at the same price, providing further funding flexibility and enhancing investor confidence in the offering.
See More
Jade Biosciences Prices Public Offering at $150 Million
- Public Offering Pricing: Jade Biosciences has announced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 million before underwriting discounts, which will significantly bolster its financial resources to support clinical trials and R&D activities.
- Underwriter Arrangement: The offering is managed by Jefferies, TD Cowen, and UBS Investment Bank as joint book-running managers, with LifeSci Capital as a passive book-running manager and BTIG as a lead manager, reflecting strong market confidence in the company.
- Use of Proceeds: Jade intends to utilize the net proceeds from this offering for clinical trials, preclinical studies, manufacturing, and additional R&D activities, aiming to accelerate the development of its therapies for autoimmune diseases and further solidify its market position.
- Compliance and Transparency: The offering is conducted under a shelf registration statement on Form S-3 that became effective on May 15, 2026, ensuring compliance and transparency, which enhances investor confidence in the company's future growth prospects.
See More
